Last reviewed · How we verify

NCT05483777

Application of Platelet-Rich Fibrin on Diabetic Foot Wound

Status unknown NA Last updated 1 February 2023
What this trial tests

NA trial testing PRF in Diabetic Foot in 14 participants. Status unknown.

Timeline
15 February 2023
Primary endpoint
30 October 2023
30 August 2024

Quick facts

Lead sponsorAbant Izzet Baysal University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment14
Start date15 February 2023
Primary completion30 October 2023
Estimated completion30 August 2024

Drugs / interventions tested

Conditions studied

Sponsor

Abant Izzet Baysal University

Who can join

18 and older, any sex, with Diabetic Foot. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was planned as a prospective case-control study to examine the effect of PRF application on wound healing in diabetic foot wound. The sample of the study will consist of patients with diabetic foot wounds, who met the inclusion criteria and agreed to participate in the study. It is planned to include 7 patients for the experimental group and 7 patients for the control group (14 patients in total). If the patient is in the experimental group, PRF will be applied to the diabetic foot wound, and in the control group, classic wound dressing (CWD) will be applied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PRF

Trials testing the same drug.

Other recruiting trials for Diabetic Foot

Currently open trials in the same condition.

Other Abant Izzet Baysal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing